Last reviewed · How we verify
EXE-346
At a glance
| Generic name | EXE-346 |
|---|---|
| Sponsor | Exegi Pharma, LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial (PHASE2)
- Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EXE-346 CI brief — competitive landscape report
- EXE-346 updates RSS · CI watch RSS
- Exegi Pharma, LLC portfolio CI